Three Dosing Schedules of Oral Rigosertib in MDS Patients
Status:
Withdrawn
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
This study will compare the dosing regimen of oral rigosertib, which has been used in other
studies of lower risk Myelodysplastic Syndrome (MDS), with 2 new dosing regimens to determine
if one of the new regimens gives improved results as measured by disease status, side
effects, and analyses of blood and urine samples.